氣霧劑療法市場 - 目前分析與預測:2021年∼2027年
Aerosol Therapy Market: Current Analysis and Forecast (2021-2027)
|出版商||UnivDatos Market Insights Pvt Ltd||商品編碼||1020676|
|出版日期||內容資訊||英文 108 Pages
|氣霧劑療法市場 - 目前分析與預測:2021年∼2027年 Aerosol Therapy Market: Current Analysis and Forecast (2021-2027)|
|出版日期: 2021年07月01日||內容資訊: 英文 108 Pages||
Aerosol therapy is the technique used to administer medication directly into the lungs and its airways. It is usually a suspension of liquids of solids administered using a medical device such as an inhaler. The Medical device converts the medication into fine aerosol particles that can be inhaled or directly propelled into the airway and lungs. The most used inhalation medications are bronchodilators and corticosteroids.
The main respiratory disorders that are currently cured using aerosol therapy include: Asthma, COPD, Bronchiectasis, cystic fibrosis, pulmonary arterial hypertension, and infectious pulmonary diseases. The novel macromolecular medications are taking aerosol therapy a step further and the therapy is being tested for non-respiratory diseases like diabetes, analgesia, and thyroid as well.
Based on product, the aerosol therapy market can be segmented into dry powder inhalers, metered dose inhalers and nebulizers. These segments can then further be sub segmented into single dose inhalers and multi dose inhalers of dry powder inhalers; conventional pressurized inhalers and soft mist inhalers of metered dose inhalers; and jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers of nebulizers. The nebulizers segment had the highest CAGR in the forecasted period on account of its ability of use in all age groups. In the past few years various types of nebulizers have been introduced. Jet nebulizers are most used in patients with pulmonary diseases as they are bulky and work only with a power source.
Based on application, the aerosol therapy market is segmented into asthma, chronic obstructive pulmonary disease, cystic fibrosis, and non-respiratory diseases, which include diabetes, analgesia and parkinson's disease. Asthma and COPD are the most treated disorders with aerosol therapy. The asthma segment had the highest CAGR value in the application segment. Asthma is highly prevalent around the world and effect 262 million people in 2019. Asthma is a long-term condition where the air passages in the lungs are partially blocked due to inflammation and muscle tightening. Symptoms of asthma include wheeze, cough, shortness of breath and tightness in chest.
Based on end-user, the aerosol therapy market is segmented into hospitals, clinics, ambulatory surgical centres, and individuals. The most common end-users are hospitals and individuals. The most common end-users are hospitals and individuals. Every year there are approximately 800,000 hospitalizations for Chronic obstructive pulmonary disease (COPD) in the United States which is the third leading cause of death in the country.
For a better understanding of the market adoption of Aerosol Therapy Industry, the market is analysed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America will dominate the Aerosol Therapy market on account of the usage respiratory disorders which are on the rise all over the world.
Some of the major players operating in the market include Merck, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis, Teva Pharmaceuticals, Opko Health, Omron Healthcare, Medtronic, and GE Healthcare. Several M&As along with partnerships have been undertaken by these players to boost their presence in different regions.